Search results for "remission"

showing 10 items of 213 documents

Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experienc…

2020

Background Malignant germ cell tumors (GCTs) are a heterogeneous group of rare neoplasms in children. Optimal outcome is achieved with multimodal therapies for patients with both localized and advanced disease, especially after the introduction of platinum-based chemotherapy regimens. In this respect, data on salvage treatment for children with relapsed or platinum-refractory disease are still limited. Methods Retrospective analysis of data regarding patients affected by malignant GCTs with platinum-refractory or relapsed disease after first-line treatment according to AIEOP TCGM 2004 protocol was conducted. Results Twenty-one patients, 15 females and 6 males, were considered for the analys…

OncologyMelphalanMalemedicine.medical_treatmentDrug ResistanceSalvage therapyrelapsed tumorsDeoxycytidineCarboplatinchemistry.chemical_compound0302 clinical medicineNeoplasmsAntineoplastic Combined Chemotherapy Protocolsgerm cell tumorsChildEtoposideIfosfamideRemission InductionHematologyNeoplasms Germ Cell and EmbryonalPrognosisgerm cell tumors; high-dose chemotherapy; pediatric tumors; refractory tumors; relapsed tumors; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child Preschool; Cisplatin; Deoxycytidine; Drug Resistance Neoplasm; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Infant; Male; Neoplasm Recurrence Local; Neoplasms Germ Cell and Embryonal; Oxaliplatin; Paclitaxel; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Salvage Therapypediatric tumorsOxaliplatinSurvival RateLocalOncology030220 oncology & carcinogenesisChild PreschoolFemalerefractory tumorsmedicine.drugmedicine.medical_specialtyAdolescentPaclitaxelThioTEPA03 medical and health sciencesInternal medicinemedicineHumansIfosfamidePreschoolSurvival rateRetrospective StudiesSalvage TherapyChemotherapybusiness.industryInfantmedicine.diseaseGemcitabineCarboplatinNeoplasm RecurrencechemistryDrug Resistance NeoplasmPediatrics Perinatology and Child HealthSettore MED/20NeoplasmGerm Cell and EmbryonalGerm cell tumorsCisplatinNeoplasm Recurrence Localbusinesshigh-dose chemotherapy030215 immunologyFollow-Up StudiesPediatric bloodcancerREFERENCES
researchProduct

Non-Hodgkin B-cell lymphoma involving the palate.

2018

Oncologymedicine.medical_specialtyLymphoma B-CellPalatal Neoplasmsbusiness.industryTreatment outcomeRemission InductionPalatal NeoplasmsChemoradiotherapymedicine.diseaseRemission inductionTreatment OutcomeOncologyInternal medicinemedicineBiomarkers TumorHumansFemalePalatal NeoplasmB-cell lymphomabusinessChemoradiotherapyHumanAgedThe Lancet. Oncology
researchProduct

From palliation to cure: PIPAC for peritoneal malignancies

2019

Introduction Systemic chemotherapy offers poor control over peritoneal disease, maybe as a consequence of restricted drug availability within the abdominal cavity. Locoregional chemotherapy may overcome these shortcomings but its administration is limited to a few patients with confined peritoneal spread. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) emerged in the last years as a novel method of intraperitoneal drug administration. Evidence acquisition We report a meta-analysis of published studies on PIPAC safety and pathological anti-tumoral efficacy on PC from various tumor entities, with the aim of providing more evidence to support further research. This systematic review a…

Oncologymedicine.medical_specialtyPalliative caremedicine.medical_treatmentSettore MED/25 - PSCHIATRIAAntineoplastic AgentsAbdominal cavityDisease03 medical and health sciences0302 clinical medicineInternal medicinemedicinePressureHumansStage (cooking)Adverse effectAerosolsChemotherapybusiness.industryRemission InductionGeneral MedicinePeritoneal carcinomatosisPeritoneal neoplasmsmedicine.anatomical_structure030220 oncology & carcinogenesisMeta-analysisPalliative care030211 gastroenterology & hepatologyDrug therapyPeritoneumbusiness
researchProduct

Clinical Significance and Biomarkers to Predict Unsustained Complete Remission in Transplant-Eligible Multiple Myeloma

2020

Background: Transplant-eligible MM patients are achieving unprecedented CR rates with frontline therapy. This urges the question about what other tests are informative upon a negative immunofixation (IFx-), as well as if patients with short duration CR continue having dismal survival with modern frontline plus salvage therapies and if so, how to predict risk of unsustained CR. Aim: To provide an optimal definition of unsustained CR and biomarkers to predict it in transplant-eligible MM patients treated with optimal therapy. Methods: A total of 262 patients enrolled in the PETHEMA/GEM2012MENOS65 trial and who were in CR after receiving six induction cycles of bortezomib, lenalidomide and dex…

Oncologymedicine.medical_specialtybusiness.industryImmunologyComplete remissionCell BiologyHematologymedicine.diseaseBiochemistryInternal medicinemedicineClinical significancebusinessMultiple myelomaBlood
researchProduct

Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib

2021

Chronic myeloid leukemia; BCR-ABL1 transcripts; Response to imatinib Leucemia mieloide crónica; Transcripciones de BCR-ABL1; Respuesta al imatinib Leucèmia mieloide crònica; Transcripcions BCR-ABL1; Resposta a imatinib The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine–kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses to IM. The objective of this study was to correlate the expression of e14a2 or e13a2 to clinical characteristics, cumulative cytogenetic and molecular responses to IM, acquisition of deep molecular response …

Oncologymedicine.medical_specialtyrelapse-free survivalLeucèmia mieloide<i>BCR</i><i>-ABL1</i> transcriptsLeucèmia mieloide crònica:Organic Chemicals::Amides::Benzamides::Imatinib Mesylate [CHEMICALS AND DRUGS]survivalArticleOncología:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Myeloid::Leukemia Myelogenous Chronic BCR-ABL Positive [DISEASES]03 medical and health sciencesBcr abl10302 clinical medicineAnàlisi de supervivència (Biometria)chronic myeloid leukemiaInternal medicinehemic and lymphatic diseasesresponse to imatinibmedicineOverall survivalHematologíaCumulative incidenceBCR-ABL1 transcriptsGene transcriptbusiness.industryRMyeloid leukemiaImatinibGeneral MedicineExpressió gènica:técnicas de investigación::métodos epidemiológicos::estadística como asunto::análisis de supervivencia [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Myeloid leukemia030220 oncology & carcinogenesisMolecular ResponseImatinib:compuestos orgánicos::amidas::benzamidas::mesilato de imatinib [COMPUESTOS QUÍMICOS Y DROGAS]MedicineRemission rateGene expression:Health Care Quality Access and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Statistics as Topic::Survival Analysis [HEALTH CARE]business:neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mielogenosa crónica BCR-ABL positiva [ENFERMEDADES]030215 immunologymedicine.drugdiscontinuation
researchProduct

Ondansetrón. Un tratamiento satisfactorio para el prurito palmoplantar refractario

2006

OndansetronRemission inductionmedicine.medical_specialtyHand Dermatosisbusiness.industryMedicineGeneral MedicineSerotoninSerotonin AntagonistsbusinessDermatologyFoot Dermatosismedicine.drugActas Dermo-Sifiliográficas
researchProduct

Prova per testimoni del pagamento e della remissione

2010

Pagamentoprova per testimoniremissioneSettore IUS/01 - Diritto Privato
researchProduct

Experimental Hepatitis

1994

Publisher Summary This chapter presents the animal models of experimental hepatitis (EAH). EAH was developed as a model of human autoimmune hepatitis (AIH). AIH in humans is a heterogeneous disease, which most often occurs in young females and generally responds very well to immunosuppressive therapy. AIH is often not recognized or is misdiagnosed as chronic non-A, non-B (non-C) viral hepatitis. Even when left untreated for considerable time periods, the disease in some patients is moderate to mild, and transient spontaneous remissions can be observed. EAH in many ways reflects this disease process. EAH also is often mild to moderate, and spontaneous remission occurs. Autoantibodies are cri…

PathogenesisHepatitisbusiness.industryImmunologyAutoantibodyMedicineIn patientSpontaneous remissionDiseaseAutoimmune hepatitisbusinessmedicine.diseaseViral hepatitis
researchProduct

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

2017

Abstract The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for …

PathologyNeoplasm ResidualInternational CooperationDiseaseReview ArticleBiochemistryEuropean LeukemiaNet0302 clinical medicineRisk Factorshemic and lymphatic diseasesCONVENTIONAL CARE REGIMENSDisease management (health)medicine.diagnostic_testACUTE MYELOGENOUS LEUKEMIAHematopoietic Stem Cell TransplantationDisease ManagementSINGLE CEBPA MUTATIONSHematology1ST COMPLETE REMISSIONHIGH-DOSE CYTARABINELeukemia Myeloid AcuteTreatment Outcome030220 oncology & carcinogenesisPractice Guidelines as TopicAdultmedicine.medical_specialtyConsensusImmunologyBUSULFAN PLUS CYCLOPHOSPHAMIDEMEDLINEMINIMAL RESIDUAL DISEASEAntineoplastic AgentsACUTE MYELOID-LEUKEMIAEnasidenibTransplantation AutologousDrug Administration ScheduleImmunophenotyping03 medical and health sciencesmedicineHumansGenetic TestingIntensive care medicineGenetic testingbusiness.industrySTEM-CELL TRANSPLANTATIONCell BiologyRANDOMIZED PHASE-IIIMinimal residual diseaseTransplantationbusinessSettore MED/15 - Malattie del Sangue030215 immunology
researchProduct

Treatment of pemphigus vulgaris with mycophenolate mofetil

1997

different pattern of diffusion changes in a 51-year-old woman with chronic epilepsy and recurrent episodes of focal status epilepticus, for whom no aetiology could be established. Status consisted of clonic jerking of the right leg, which continued for 22 days and was followed by transient paresis. DWI during status showed decreased diffusion in the motor cortex of the right leg (relative decrease in ADC of 27%, see figure). Surprisingly, the diffusion was increased in the subcortical white matter (relative increase in ADC of 31%). On the T2-weighted image (not shown), both cortex and subcortical white matter of the corresponding region returned a high signal similar to previously reported …

Pathologymedicine.medical_specialtyPrednisoloneAnti-Inflammatory AgentsMycophenolateMycophenolic acidWhite matterIMP DehydrogenaseCortex (anatomy)medicineHumansPremovement neuronal activityParesisbusiness.industryRemission InductionPemphigus vulgarisGeneral MedicineMycophenolic Acidmedicine.diseasemedicine.anatomical_structureDrug Therapy Combinationmedicine.symptombusinessImmunosuppressive AgentsPemphigusmedicine.drugMotor cortexThe Lancet
researchProduct